Targeted Therapy in Ovarian Cancer

Por Willmott, Lyndsay J., Fruehauf, John P.
Publicado em 2010

Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture

Por Trapp, Valerie, Parmakhtiar, Basmina, Papazian, Vartan, Willmott, Lyndsay, Fruehauf, John P.
Publicado em 2010

Phase II clinical trial evaluating docetaxel, vinorelbine and GM-CSF in stage IV melanoma

Por Eroglu, Zeynep, Kong, Kevin M., Jakowatz, James G., Samlowski, Wolfram, Fruehauf, John P.
Publicado em 2011

Thrombospondin-1 expression in melanoma is blocked by methylation and targeted reversal by 5-Aza-deoxycytidine suppresses angiogenesis

Por Lindner, Daniel J., Wu, Yan, Haney, Rebecca, Jacobs, Barbara S., Fruehauf, John P., Tuthill, Ralph, Borden, Ernest C.
Publicado em 2012

PROSPECTIVE EVALUATION OF AN IN VITRO RADIATION RESISTANCE ASSAY IN LOCALLY ADVANCED CANCER OF THE UTERINE CERVIX: A SOUTHWEST ONCOLOGY GROUP STUDY

Por Randall, Leslie M, Monk, Bradley J, Moon, James, Parker, Ricardo, Al-Ghazi, Muthana, Wilczynski, Sharon, Fruehauf, John P, Markman, Maurie, Burger, Robert A
Publicado em 2010

Prediction of drug response in breast cancer using integrative experimental/computational modeling

Por Frieboes, Hermann B., Edgerton, Mary E., Fruehauf, John P., Rose, Felicity R. A. J., Worrall, Lisa K., Gatenby, Robert A., Ferrari, Mauro, Cristini, Vittorio
Publicado em 2009

Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study

Por Randall, Leslie M., Monk, Bradley J., Darcy, Kathleen M., Tian, Chunqiao, Burger, Robert A., Liao, Shu-Yuan, Peters, William A., Stock, Richard J., Fruehauf, John P.
Publicado em 2008

Prognostic Relevance of Carbonic Anhydrase-IX in High-Risk, Early-Stage Cervical Cancer: A Gynecologic Oncology Group Study

Por Liao, Shu-Yuan, Darcy, Kathleen M., Randall, Leslie M., Tian, Chunqiao, Monk, Bradley J., Burger, Robert A., Fruehauf, John P., Peters, William A., Stock, Richard J., Stanbridge, Eric J.
Publicado em 2009

PREDICTIVE AND PROGNOSTIC ANGIOGENIC MARKERS IN A GYNECOLOGIC ONCOLOGY GROUP PHASE II TRIAL OF BEVACIZUMAB IN RECURRENT AND PERSISTENT OVARIAN OR PERITONEAL CANCER

Por Han, Ernest S., Burger, Robert A., Darcy, Kathleen M., Sill, Michael W., Randall, Leslie M., Chase, Dana, Parmakhtiar, Basmina, Monk, Bradley J., Greer, Benjamin E., DeGeest, Koen, Fruehauf, John P.
Publicado em 2010

BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma

Por Kim, Kevin B., Sosman, Jeffrey A., Fruehauf, John P., Linette, Gerald P., Markovic, Svetomir N., McDermott, David F., Weber, Jeffrey S., Nguyen, Hoa, Cheverton, Peter, Chen, Daniel, Peterson, Amy C., Carson, William E., O'Day, Steven J.
Publicado no J Clin Oncol (2012)